Programmed Cell Death Receptor | List of Frontiers open access articles

Case Report

Published on 25 Sep 2018

Management of Persistent Pruritus and Lichenoid Reaction Secondary to Nivolumab With Narrowband Ultraviolet B Phototherapy

in Pharmacology of Anti-Cancer Drugs

Marie Donaldson
Joshua L. Owen
Young K. Chae
Jennifer N. Choi

Frontiers in Oncology

doi 10.3389/fonc.2018.00405

10,205 views
18 citations

Review

Published on 23 Dec 2021

What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?

in Cancer Immunity and Immunotherapy

Qingyi Wang
Bin Xie
Shuang Liu
Ying Shi
Yongguang Tao
Desheng Xiao
Wenxiang Wang

Frontiers in Immunology

doi 10.3389/fimmu.2021.773168

15,466 views
36 citations

Review

Published on 28 Oct 2024

Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma

in Cancer Immunity and Immunotherapy

Zeping Wang
Xiaojing Zou
Haiyan Wang
Zhihui Hao
Gebin Li
Shuaiyu Wang

Frontiers in Immunology

doi 10.3389/fimmu.2024.1454720

5,850 views
4 citations

Original Research

Published on 09 Jun 2023

Efficacy and safety of programmed cell death receptor 1 inhibition-based regimens in patients with pediatric malignancies: the real-world study in China

in Cancer Immunity and Immunotherapy

Ye Hong
Mengjia Song
Yingxia Lan
Juan Wang
Suying Lu
Yu Zhang
Jia Zhu
Feifei Sun
Junting Huang
Juan Liu

Frontiers in Immunology

doi 10.3389/fimmu.2023.1182751

3,939 views
4 citations

Review

Published on 28 Mar 2024

Programmed cell death-ligand 2: new insights in cancer

in Cancer Immunity and Immunotherapy

Yukang Yang
Xia Yan
Xueqi Bai
Jiayang Yang
Jianbo Song

Frontiers in Immunology

doi 10.3389/fimmu.2024.1359532

6,364 views
13 citations

Review

Published on 30 Mar 2022

Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy

in Gastrointestinal Cancers: Gastric and Esophageal Cancers

Daijun Wang
Yanmei Gu
Xin Yan
Chengdong Huo
Guan Wang
Yang Zhao
Muzhou Teng
Yumin Li

Frontiers in Oncology

doi 10.3389/fonc.2022.844260

14,710 views
27 citations

Case Report

Published on 30 Apr 2021

Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab

in Multiple Sclerosis and Neuroimmunology

Salma Charabi
Lotte Engell-Noerregaard
Anna Christine Nilsson
Christian Stenör

Frontiers in Neurology

doi 10.3389/fneur.2021.655283

6,208 views
26 citations

Review

Published on 24 Jul 2023

Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy

in Cancer Immunity and Immunotherapy

Chong Feng
Lening Zhang
Xin Chang
Dongliang Qin
Tao Zhang

Frontiers in Immunology

doi 10.3389/fimmu.2023.1230135

13,691 views
40 citations

Mini Review

Published on 29 Aug 2022

Tumor acidity: From hallmark of cancer to target of treatment

in Cancer Metabolism

Alexey Bogdanov
Andrey Bogdanov
Viacheslav Chubenko
Nikita Volkov
Fedor Moiseenko
Vladimir Moiseyenko

Frontiers in Oncology

doi 10.3389/fonc.2022.979154

24,882 views
144 citations

Original Research

Published on 20 Dec 2018

Novel Role for PD-1:PD-L1 as Mediator of Pulmonary Vascular Endothelial Cell Functions in Pathogenesis of Indirect ARDS in Mice

in Molecular Innate Immunity

Joanne Lomas-Neira
Sean F. Monaghan
Xin Huang
Eleanor A. Fallon
Chun-Shiang Chung
Alfred Ayala

Frontiers in Immunology

doi 10.3389/fimmu.2018.03030

24,426 views
45 citations

Case Report

Published on 28 Jul 2020

Early Onset Immune-Related Adverse Event to Identify Pseudo-Progression in a Patient With Ovarian Cancer Treated With Nivolumab: A Case Report and Review of the Literature

in Obstetrics and Gynecological Surgery

Hui Li
Xin Zhou
Ding Zhang
Guoqiang Wang
Xiaochun Cheng
Caihong Xu
Bin Yao
Linrong Pang
Jun Chen

Frontiers in Medicine

doi 10.3389/fmed.2020.00366

4,171 views
8 citations

Original Research

Published on 06 Oct 2022

Molecular dynamics identifies semi-rigid domains in the PD-1 checkpoint receptor bound to its natural ligand PD-L1

in Cell and Gene Therapy

Michael Kenn
Rudolf Karch
Lisa Tomasiak
Michael Cibena
Georg Pfeiler
Heinz Koelbl
Wolfgang Schreiner

Frontiers in Bioengineering and Biotechnology

doi 10.3389/fbioe.2022.838129

2,851 views
5 citations

Original Research

Published on 22 Dec 2016

Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells

in Cancer Immunity and Immunotherapy

Anja Derer
Martina Spiljar
Monika Bäumler
Markus Hecht
Rainer Fietkau
Benjamin Frey
Udo S. Gaipl

Frontiers in Immunology

doi 10.3389/fimmu.2016.00610

15,467 views
131 citations

Original Research

Published on 20 Nov 2024

Discovery and preclinical evaluation of BPB-101: a novel triple functional bispecific antibody targeting GARP-TGF-β complex/SLC, free TGF-β and PD-L1

in Cancer Immunity and Immunotherapy

Wenxin Xu
Jieying Xu
Pingcui Li
Deyu Xu
Hongjie Cheng
Huan Zheng
Li Zhang
Mengmeng Liu
Siyuan Ye
Mengshi Jiang

Frontiers in Immunology

doi 10.3389/fimmu.2024.1479399

4,517 views
2 citations

Systematic Review

Published on 25 Nov 2021

Prognostic Significance of PD-L1 Expression In Patients With Primary Oropharyngeal Squamous Cell Carcinoma: A Meta-Analysis

in Head and Neck Cancer

Jerry Polesel
Anna Menegaldo
Giancarlo Tirelli
Vittorio Giacomarra
Roberto Guerrieri
Lorena Baboci
Mariateresa Casarotto
Valentina Lupato
Giuseppe Fanetti
Paolo Boscolo-Rizzo

Frontiers in Oncology

doi 10.3389/fonc.2021.787864

4,265 views
20 citations

Original Research

Published on 22 Jun 2023

PD-L1 and tumor-infiltrating CD8+ lymphocytes are correlated with clinical characteristics in pediatric and adolescent pituitary adenomas

in Cancer Endocrinology

Mengwu Shi
Yifu Song
Yaochuan Zhang
Longjie Li
Juanhan Yu
Ana Hou
Sheng Han

Frontiers in Endocrinology

doi 10.3389/fendo.2023.1151714

3,627 views
8 citations

Articles

Management of Persistent Pruritus and Lichenoid Reaction Secondary to Nivolumab With Narrowband Ultraviolet B Phototherapy

What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?

Companion diagnostics and predictive biomarkers for PD-1/PD-L1 immune checkpoint inhibitors therapy in malignant melanoma

Efficacy and safety of programmed cell death receptor 1 inhibition-based regimens in patients with pediatric malignancies: the real-world study in China

Programmed cell death-ligand 2: new insights in cancer

Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy

Case Report: Longitudinal Extensive Transverse Myelitis With Novel Autoantibodies Following Two Rounds of Pembrolizumab

Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy

Tumor acidity: From hallmark of cancer to target of treatment

Novel Role for PD-1:PD-L1 as Mediator of Pulmonary Vascular Endothelial Cell Functions in Pathogenesis of Indirect ARDS in Mice

Early Onset Immune-Related Adverse Event to Identify Pseudo-Progression in a Patient With Ovarian Cancer Treated With Nivolumab: A Case Report and Review of the Literature

Molecular dynamics identifies semi-rigid domains in the PD-1 checkpoint receptor bound to its natural ligand PD-L1

Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells

Discovery and preclinical evaluation of BPB-101: a novel triple functional bispecific antibody targeting GARP-TGF-β complex/SLC, free TGF-β and PD-L1

Prognostic Significance of PD-L1 Expression In Patients With Primary Oropharyngeal Squamous Cell Carcinoma: A Meta-Analysis

PD-L1 and tumor-infiltrating CD8+ lymphocytes are correlated with clinical characteristics in pediatric and adolescent pituitary adenomas